Bio-Techne Corp
TECH
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.29B
Close$
$25.59
64.5% downside
Current Fair Value
64.5% downsideOvervalued by 64.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.29 Billion |
|---|---|
| Enterprise Value | $11.41 Billion |
| Dividend Yield | $0.32 (0.44%) |
| Earnings per Share | $0.47 |
| Beta | 1.29 |
| Outstanding Shares | 155,893,000 |
Return
| Return on Equity | 5.25% |
|---|---|
| Return on Assets | 4.30% |
| Return on Invested Capital | 6.48% |
Valuation & Multiples
| P/E Ratio | 101.54 |
|---|---|
| PEG | 80.56 |
| Price to Sales | 10.29 |
| Price to Book Ratio | 5.54 |
| Enterprise Value to Revenue | 9.42 |
| Enterprise Value to EBIT | 73.4 |
| Enterprise Value to Net Income | 104 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.52
Average shareholder expectationRevenue Estimate
$314.63 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$0.52
Average shareholder expectationRevenue Estimate
$314.63 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 285.16% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 500▼ 99.97% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.44%▼ 109.36% |
|---|---|
| Total Invested | $491.49M▼ 94.71% |
| Investors Holding | 187▼ 416.00% |
ESG Score
No data
About Bio-Techne Corp
2,100 employees
CEO: Charles Kummeth Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's brands include flagship R&D Systems , No...